gMendel
Dimitrios Kyriakidis is an experienced business development professional with a diverse background in sales and marketing within the medical and pharmaceutical industries. Currently serving as Business Development Manager at gMendel since 2020, Dimitrios has previously held key roles such as Senior Business Development Manager at Sportalius and Product Manager & Sales Representative at Johnson & Johnson, where responsibilities included managing products and sales in orthopaedic medical devices. Dimitrios began a career in medical sales as a Sales Representative at Stryker and brings consulting experience from SAP, contributing to major projects for several notable organizations. Additional entrepreneurial experience includes co-founding Red, Blue & Yellow, focusing on market penetration strategies. Educational credentials feature ongoing studies at Esade and a Bachelor's degree in Business Administration from Inholland University, complemented by a digital marketing program at Santa Clara University.
This person is not in any teams
This person is not in any offices
gMendel
AI-powered, vertically-integrated IVD certified technology for accurate, fast and affordable diagnosis of genetic disorders & beyond. There are 350 million people worldwide suffering from >10,000 genetic disorders / rare diseases, but <500 of these diseases have an approved treatment. The societal burden of the rare diseases exceeds €2 trillion, demonstrating an apparent unmet clinical need for better, faster & affordable Companion Diagnostics of rare diseases towards precision treatments. Today, the diagnosis of rare diseases, that takes on average 7 years, is based on the current sequencing technologies, has a high cost and complexity and leaves many patients undiagnosed. gMendel® is the only end-to-end cloud based technology that uses AI for accurate, fast & affordable diagnosis of multiple rare diseases & beyond. Moreover, gMendel®’s technology is automated, transcending the need for bioinformatician’s intervention, reducing the experimental errors & costs. This improves accessibility and has a potential to revolutionize genetic analysis without any change to current health care protocols. Compared to current available technologies in the market, our novel combination of genomics & AI makes our technology better, faster, and more affordable than any other in the companion diagnostics market. In 2022, gMendel® obtained CE mark under EU IVDD, becoming the world’s first IVD certified technology for human genetic disorders utilizing long read sequencing technology and AI. gMendel® has achieved Proof of Concept to detect deletions, insertions, point mutations by doing whole exome sequencing or DNA region customisation by amplicons or probes. We are currently in the process to commercialise our technology for Companion Diagnostics for Anemia, Epilepsy, Cystic Fibrosis & Spinal Muscular Atrophy.